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Abstract. Nitrogen-containing bisphosphonates (N-BPs) are the 
most widely used anti-resorptive agents in the treatment of bone-
related diseases. N-BPs inhibit bone resorption by specifically 
targeting osteoclasts, bone-resorbing cells. However, soft tissue 
toxicity, such as oral or gastrointestinal (GI) ulcerations has 
frequently been reported in N-BP users, suggesting that N-BPs 
may also directly target cells other than osteoclasts. Previously, 
we reported that BPs inhibit proliferation without inducing 
the apoptosis of normal human oral keratinocytes (NHOKs). 
However, the molecular mechanisms through which N-BPs inhibit 
the proliferation of NHOKs are not yet fully understood. In this 
study, we performed gene expression profiling in N-BP-treated 
NHOKs and identified cyclin A2 as one of the most commonly 
downregulated genes. When the NHOKs were treated with N-BPs, 
we found that the level of cyclin A2 was suppressed in a dose- and 
time-dependent manner. In addition, the protein level of cyclin A2 
was also significantly lower in oral epithelial cells in N-BP-treated 
oral mucosal tissue constructs. Cyclin A2 promoter reporter assay 
revealed that N-BPs inhibited the luciferase activity, indicating that 
the inhibition of cyclin A2 expression occurs at the transcriptional 
level. Furthermore, N-BPs did not alter the expression of cyclin A2 
in normal human oral fibroblasts (NHOFs), suggesting that the 
effect of N-BPs on cyclin A2 expression may be cell-type specific. 
Thus, the findings of our study demonstrate that the inhibition 
of NHOK proliferation by N-BPs is mediated, at least in part, 
by the suppression of cyclin A2 expression at the transcriptional 
level, which may explain the underlying mechanisms of soft tissue 
toxicity by N-BPs.
Introduction
Nitrogen-containing bisphosphonates (N-BPs) are the most 
commonly used anti-resorptive agents in the treatment of 
bone-related diseases, such as osteoporosis and metastatic bone 
diseases (1). Due to their ability to bind and chelate calcium, 
N-BPs are preferentially localized to the bone matrix comprised 
of calcium-enriched inorganic hydroxyapatite (2). N-BPs exert 
their anti-resorptive effects by nullifying the functions of 
osteoclasts, the only bone-resorbing cells in the body; N-BPs 
are taken up by osteoclasts, as these cells resorb bone. Clinical 
studies suggest that N-BPs have side-effects on tissues other than 
bone, such as epithelial tissues (3). Indeed, gastrointestinal (GI) 
toxicity is one of the major side-effects of BP and a leading 
cause of therapy termination during N-BP clinical trials (4). 
Esophageal/oral inflammation and ulceration are frequently 
noted in N-BP-users (5,6). These studies suggest that N-BP may 
have direct effects on epithelial cells.
The epithelium is also known to be highly enriched in 
calcium contents, such that the concentration of calcium 
gradually increases from the basal to the outer layers (7). We 
previously found that N-BPs localize not only to bone, but also 
to the epithelium, as demonstrated by fluorescently-labeled 
N-BPs in osteomucosal tissue constructs (8). We also reported 
that N-BPs inhibit proliferation by inducing cell cycle arrest at 
the S phase without inducing the apoptosis of normal human 
oral keratinocytes (NHOKs) (9). Nonetheless, the molecular 
mechanisms underlying the suppressive effects of N-BPs on 
the proliferation of keratinocytes remain unclear.
In our continual efforts to elucidate the molecular mecha-
nisms of N-BP on NHOKs, in this study, we performed gene 
expression profiling with DNA microarray on NHOKs treated 
with either pamidronate (PAM) or zoledronate (ZOL), two of 
which are the most frequently used N-BPs in clinical prac-
tice. Using this high-throughput approach, we identified and 
validated cyclin A2 as one of the bisphosphonate target genes 
associated with S phase cell cycle arrest and the inhibition of 
cell proliferation.
Materials and methods
Cells and cell culture. Primary NHOKs and normal human 
oral fibroblasts (NHOFs) were obtained according to previ-
ously described methods (9) following the approval of the 
Institutional Review Board (IRB# 04-060-04). Briefly, 
discarded oral mucosal tissues were collected without identi-
fiers from the normal patients who are undergoing routine 
dental procedures (e.g., gingivectomy for the crown-lengthening 
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procedures). The obtained oral mucosal tissues were cut into 
25 mm2 x 0.5 mm sections and incubated in 2.5 mg/ml dispase 
solution (Cat. no. 17105; Gibco, Grand Island, NY, USA) in 37˚C 
for 1 h, after which the epithelial layers and connective layers 
were separated. The separated epithelial layers were minced 
and subjected to trypsin digestion (Cat. no. 25200056; Gibco) 
in 37˚C for 5 min to harvest the NHOKs. The separated connec-
tive tissue layers were minced and subjected to collagenase 
digestion (Cat. no. 17100017; Gibco) in 37˚C for1 h to harvest 
the NHOFs. The NHOKs were cultured in EpiLife supple-
mented with human keratinocyte growth supplement (HKGS) 
(Cascade Biologics, Portland, OR, USA), and the NHOFs were 
cultured in DMEM supplemented with 10% FBS (Invitrogen, 
Carlsbad, CA, USA). ZOL and PAM were purchased from LKT 
Laboratories, Inc. (St. Paul, MN, USA). Throughout the study, 
1, 2, and 4 µM of ZOL and 10, 20 and 50 µM of PAM were used 
to treat the cells for the indicated periods of time. 
DNA microarray. Gene expression profiling was performed 
using the Affymetrix GeneChip Human Genome U133 Plus 2.0 
Array (Affymetrix, Santa Clara, CA, USA). Total RNA was 
extracted from the cells using the RNeasy mini kit (Qiagen, 
Hilden, Germany) according to the manufacture's instructions. 
RNA integrity was evaluated using an Agilent 2100 Bioanalyzer 
(Agilent Technologies, Palo Alto, CA, USA) and the purity/
concentration was determined using a NanoDrop 8000 spec-
trophotometer (NanoDrop Products, Wilmington, DE, USA). 
Microarray experiments were performed at UCLA Clinical 
MIcroarray Core (CMC). Microarray targets were prepared 
using NuGEN WT-Ovation Formalin-Fixed Paraffin-Embedded 
RNA Amplification System and FL-Ovation cDNA Biotin 
Module V2 (NuGEN Technologies, San Carlos, CA, USA) and 
then hybridized to the array, all according to the manufacturers' 
instructions. The arrays were washed and stained with strepta-
vidin phycoerythrin in Affymetrix Fluidics Station 450 using 
the Affymetrix GeneChip protocol, and then scanned using an 
Affymetrix GeneChip Scanner 3000. The acquisition and initial 
quantification of array images were conducted using the AGCC 
software (Affymetrix). The subsequent data analyses were 
performed using Partek Genomics Suite Version 6.4 (Partek, 
St. Louis, MO, USA). Differentially expressed genes were 
selected at ≥2-fold and P<0.005. Ingenuity Pathway Analysis 
was also performed by the UCLA CMC laboratory.
Conventional and reverse transcription-quantitative 
PCR (RT-qPCR). Total RNA was isolated from the cultured 
cells using TRIzol™ reagent (Invitrogen) and was then 
subjected to RNases-free DNase I digestion at 37˚C for 2 h 
to eliminate any genomic DNA contamination. DNA-free 
total RNA (5 µg) was dissolved in 15 µl diethylpyro-
carbonate-treated water, and the reverse transcription 
reaction was performed in First-Strand buffer containing 
300 U SuperScript II (both from Invitrogen) with 10 mM DTT 
and 0.5 µg random hexamer (Promega, Madison, WI, USA) 
and 125 µM deoxynucleoside triphosphates. The annealing 
reaction was carried out for 5 min at 65˚C, and complementary 
DNA synthesis was performed for 2 h at 37˚C, followed by 
incubation for 15 min at 70˚C to terminate the enzyme reac-
tion. The reverse transcription product was diluted with 70 µl 
H2O. Conventional PCR was performed in triplicate for each 
2 µl cDNA and the resultant PCR amplicants were visualized 
by running the agarose gel. Quantitative (real-time) (qPCR) 
was performed in triplicate for each 1 µl cDNA sample with 
LC480 SYBR-Green I master using universal cycling condi-
tions on LightCycler 480 from Roche (Indianapolis, IN, USA). 
A total of 45 cycles were executed, and the second derivative 
Cq value determination method was used to compare fold 
differences. The primer sequences were obtained from the 
Universal Probe Library (Roche). The following primers were 
used for PCR amplification: glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) primers, 5'-GAC CCC ATT GAC CTC 
AAC-3' (forward) and 5'-CTT CTC CAT GGT GGT GAA 
GA-3' (reverse); and cyclin A2 primers, 5'-GAG GAC CAG 
GAG AAT ATC AAC CCG G-3' (forward) and 5'-AGC CAG 
GGC ATC TTC ACG CTC TAT T-3' (reverse). RT-qPCR was 
also performed to confirm the data obtained from microarray 
analyses as described above and using the primer sequences 
listed in Table I.
Table I. Primer sequences used for PCR.
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Western blot analysis. The cells were lysed and subjected 
to western blot analysis as previously described (9). Briefly, 
the cells were washed twice with PBS prior to treatment 
with ice-cold lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 5 mM EDTA and 1% Triton X-100).  The cells were 
then scraped and incubated on ice for 10 min. Cell debris was 
separated by centrifugation at 20,000 x g at 4˚C for 20 min 
and the supernatant was collected for western blot analysis 
after being subjected to 8 or 10% SDS-PAGE. Following 
electrophoresis, the proteins were transferred onto immo-
bilized membranes (Millipore, Billerica, MA, USA), which 
were subsequently blocked with 5% non-fat milk for 1 h at 
room temperature. The membranes were then incubated with 
primary antibodies, and probed with the respective secondary 
antibodies conjugated with HRP. The signals were obtained 
using ChemiDoc XRS system (Bio-Rad, Hercules, CA, USA). 
The following primary antibodies were used: cyclin A2 (C-19), 
cyclin D1 (C-20; sc-717), Cdk6 (C-21; sc-117), Cdk2 (M2; 
sc-163) and β-actin (I-19; sc-1616) (all from Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA); and proliferating 
cell nuclear antigen (PCNA) (Ab-1; NA03-200UG) from 
Oncogene Research Product (Boston, MA, USA).
Analysis of BP-responsive reporter activity. The cyclin A2- 
promoter luciferase reporter vector (pGL3-cyclinA2p) was 
constructed by inserting a region of the cyclin A2 promoter 
(-516 to +92) into the pGL3-basic plasmid (Promega). Briefly, 
the cyclin A2 promoter was PCR-amplified from the pALUC-
cyclin A2 reporter plasmid, kindly provided by Dr Berthold 
Henglein (Institut National de la Santé et de la Recherche 
Médicale, Paris, France). The 608 bp cyclin A2 promoter region 
was cloned into the cloning vector, cut out by double-digesting 
with SacI (New England Biolabs, Beverly, MA, USA) and 
XhoI (Invitrogen), and ligated into the pGL3-basic plasmid. 
The correct sequence was confirmed using sequencing anal-
ysis. The cells were transfected with 1 µg of either pGL3-basic 
or pGL3-cyclinA2p using Lipofectamine 2000 (Invitrogen). 
The pRL-SV40 plasmid (0.005 µg/well) containing the Renilla 
luciferase gene driven by the SV40 promoter was co-transfected 
as a control. After 48 h, the cells were harvested, and luciferase 
activity was measured using the Dual Luciferase Reporter 
assay system using a luminometer (both from Promega). The 
experiment was performed in triplicate.
Organotypic 3-dimensional (3D) raft cultures. The cells were 
grown as organotypic raft cultures using previously established 
techniques (9). Briefly, 1x106 cells were seeded on the submucosal 
equivalents consisting of type I collagen and NHOFs. The cells 
were grown to confluence, submerged in culture medium, and 
then exposed to the liquid-air interface by lowering the medium 
level. The cultures were maintained in this ‘rafting’ fashion for 
14 days and were harvested by fixing in 10% buffered formalin. 
Subsequently, hematoxylin and eosin (H&E) staining was 
performed on 6-µm-thick sagittal sections of each reconstructs 
to reveal the histological features. Sample processing, paraffin 
embedding, sectioning and H&E staining were performed at the 
Translational Pathology Core Laboratory at UCLA.
Immunohistochemical (IHC) staining. IHC staining was 
performed on the organotypic raft culture samples as previ-
ously described (9). Cyclin A2 expression was determined 
in bisphosphonate-treated or -untreated oral mucosal tissue 
samples from raft cultures, which were formalin-fixed, paraffin-
embedded and sectioned. The specimens were subjected to 
IHC analysis for the expression of cyclin A2 (C-19; Santa Cruz 
Biotechnology, Inc.) at 1:200 concentrations. Stained tissues 
were developed using the 3,3'-diaminobenzidine (DAB) chro-
mogen substrate (Vector Laboratories, Inc., Burlingame, CA, 
USA). The samples were counterstained with hematoxylin.
Statistical analysis. The results are expressed as the 
means ± standard deviation. For the comparison, the outcome 
measurements were compared to the control group using the 
Student's t-test. Values of p<0.05 are considered significant.
Results
Gene expression profiling in ZOL or PAM-treated NHOKs. 
Previously, we demonstrated that N-BPs inhibit proliferation 
without causing the apoptosis of NHOKs (9). In this study, to 
elucidate the mechanisms through which N-BPs inhibit cell 
proliferation, we performed gene expression profiling using 
NHOKs treated with PAM or ZOL at concentrations that cause 
a significant loss of proliferation (data not shown). We used 
various concentrations of PAM and ZOL as ZOL is 2-4-fold 
more potent than PAM (10). In the ZOL-treated NHOKs, 
480 genes were differentially expressed, whereas 383 genes 
were differentially expressed in the PAM-treated NHOKs 
when compared to the untreated NHOKs (Fig. 1A). From these 
data, we identified 280 genes that were commonly present in 
both the ZOL- and PAM-treated NHOKs (Fig. 1A). Ingenuity 
Pathway Analysis (IPA) revealed that, of these 280 genes, many 
of them were associated with cell cycle control of chromosomal 
replication (Fig. 1B). Indeed, genes related to cell cycle regula-
tion, such as cell division cycle(CDC)20, CDC6, cyclin (CCN)
A2, CCNB1, E2F transcription factor 8 (E2F8) and CDC2, 
were downregulated by the bisphosphonates, whereas genes 
that are more involved in structural formation, such as 
matrix metallopeptidase 10 (MMP10), late cornified enve-
lope 3E (LCE3E), MAF BZIP transcription factor B (MAFB), 
SLIT and NTRK like family member 6 (SLITRK6), late 
cornifiedenvelope 3D (LCE3D) and interferon induced protein 
with tetratricopeptide repeats 1 (IFIT1), exhibited an increased 
expression (Table II and Fig. 1C). To confirm the data from 
the microarray analysis, we performed RT-qPCR and found 
consistent results (Fig. 1D and E), supporting the validity of the 
microarray data.
N-BPs inhibit the expression of cyclin A2. As previously 
demonstrated, when NHOKs were treated with the BPs, 
they underwent cell cycle arrest at the S phase (9,11). As 
our microarray data revealed the effects of N-BPs on genes 
associated with the cell cycle, we screened for cell cycle-
related proteins. When the NHOKs were treated with PAM, 
the expression of PCNA, a proliferation marker, decreased in 
time- and dose-dependent manner (Fig. 2A). Consistent with 
the microarray data, the expression of cyclin A2, a protein 
that is associated with the S phase in the cell cycle, was 
markedly diminished to an undetectable level by PAM. The 
dose-dependent decrease in cyclin A2 expression was also 
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observed in the ZOL-treated NHOKs (Fig. 2B). Previously, 
we also demonstrated that BPs induce inhibitory effects on 
epithelial tissues using oral mucosal tissue constructs (9). 
To examine whether the anti-proliferative effects of BPs on 
epithelial tissues are associated with cyclin A2 expression, 
we treated the oral mucosal tissue constructs with ZOL. As 
expected, tissue atrophy with thinning of the epithelial layers 
was observed (Fig. 2C). We then performed IHC staining for 
cyclin A2 in the ZOL-treated oral mucosal tissue constructs. 
The results revealed a marked reduction in cyclin A2 
staining patterns in the epithelial layer of the ZOL-treated 
tissues (Fig. 2D). Collectively, these data indicate that the 
suppression of cell proliferation at the S phase is associated 
with the suppression of cyclin A2 expression.
N-BPs inhibit cyclin A2 expression at the transcriptional 
level. To further examine the molecular mechanisms through 
which bisphosphonates regulate the expression of cyclin A2, 
we examined expression of cyclin A2 at the transcriptional 
level. Similar to the results of western blot analysis, the mRNA 
level of cyclin A2 decreased in a time- and dose-dependent 
manner (Fig. 3A). To further confirm this finding, we constructed 
Table II. Differentially expressed genes by N-BPs (fold induction).
Gene symbol Gene title CTL vs PAM/ZOL CTL vs PAM CTL vs ZOL
CLDN11 Claudin 11 -7.48 -7.34 -7.62
CDC20 Cell division cycle 20 homolog -4.59 -3.77 -5.58
CDC6 Cell division cycle 6 homolog -4.08 -3.83 -4.36
CDKN3 Cyclin-dep kinase inhibitor 3 -3.89 -3.37 -4.49
LMNB1 Lamin B1 -3.82 -3.41 -4.27
CCNA2 Cyclin A2 -3.78 -3.53 -4.05
CCNB1 Cyclin B1 -3.44 -3.14 -3.77
EPCAM Epithelial cell adhesion molecule -3.44 -3.64 -3.24
E2F8 E2F transcription factor 8 -3.37 -3.24 -3.51
HMGB2 High-mobility group box 2 -3.1 -2.95 -3.26
CDC2 Cell division cycle 2 -2.87 -3.03 -2.71
FOXM1 Forkhead box M1 -2.72 -2.6 -2.85
HNRNPD Hn ribonuclearprotein D -2.57 -2.3 -2.88
CDKN2C Cyclin-dep kinase inhibitor 2C -2.5 -2.32 -2.68
RBL1 Retinoblastoma-like 1 (p107) -2.28 -2.31 -2.25
FOXA2 Forkhead box A2 -2.26 -2.37 -2.15
BRCA2 Breast cancer 2, early onset -2.25 -2.31 -2.2
RAD51 RAD51 homolog -2.21 -2.12 -2.3
MSH2 musS homolog 2 -2.18 -2.17 -2.18
EZH2 Enhancer of zeste homolog 2 -2.18 -2.17 -2.18
RAD54B RAD54 homolog B -2.16 -2.15 -2.17
LCE3E Late cornified envelope 3E 1.79 1.57 2.05
SLITRK6 SLIT and NTRK-like family,  2.08 1.88 2.29
 member 6
TP53INP2 p53 inducible nuclear protein 2 2.13 2.01 2.24
CD24 CD24 molecule 2.19 2.22 2.16
TNFSF10 TNF superfamily member 10 2.43 2.45 2.4
MMP10 Matrix metallopeptidase 10 2.24 2.25 2.22
MAFB V-maf musculoaponeurotic 2.31 2.38 2.24
 fibrosarcoma oncogene homolog B
TP53INP1 p53 inducible nuclear protein 1 2.37 2.35 2.39
SOX4 SRY-box 4 2.59 2.63 2.54
LCE3D Late cornified envelope 3D 2.65 2.68 2.63
FN1 Fibronectin 1 2.9 2.7 3.11
IFIT1 Interferon-induced protein 2.93 3.53 2.43
 with tetratricopeptide repeats 1
IL6 Interleukin 6 3.34 2.95 3.79
N-BPs, nitrogen-containing bisphosphonates; PAM, pamidronate; ZOL, zoledronate.
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Figure 2. Nitrogen-containing bisphosphonates (N-BPs) inhibit the expression of cyclin A2. (A) Νormal human oral keratinocytes (NHOKs) were treated with 
10 µM pamidronate (PAM) for 2 or 4 days. NHOKs were also treated with 10 or 50 µM PAM for 4 days. Cell lysates were subjected to western blot analysis for 
PCNA, cyclin D1, Cdk6, cyclin A2, Cdk2 and β-actin. (B) NHOKs were treated with 1 or 2 µM zoledronate (ZOL) and cyclin A2 expression was examined by 
western blot analysis. (C) Oral mucosal tissues were constructed, and 4 µM ZOL was treated for 7 days. Immunohistochemical staining was performed using 
cyclin A2 antibody (1:200). IgG was used as a negative control. (D) The cyclin A2 staining pattern in the epithelial tissue layers were quantified by counting 
DAB-positive cells in 3 independent fields of oral mucosal tissue constructs. ***p<0.001.
Figure 1. Gene expression profiling in zoledronate (ZOL)- or pamidronate (PAM)-treated normal human oral keratinocytes (NHOKs). (A) NHOKs were treated 
without or with 10 µM PAM or 4 µM ZOL for 4 days (n=3), and subjected to gene expression profiling using DNA microarray. Venn diagram of the differentially 
regulated genes by ZOL or PAM. (B) Ingenuity Pathway Analysis (IPA) of genes commonly regulated by both ZOL and PAM. (C) Heatmap representing the 
decreased gene expression (top of heatmap) and increased gene expression (bottom of heatmap) in N-BP-treated NHOKs compared to the controls. NHOKs were 
treated with 4 µM ZOL or 10 µM PAM for 4 days and RT-qPCR was performed to validate genes that are (D) downregulated or (E) upregulated. Gene expression 
was normalized to GAPDH. *p<0.05; **p<0.01; ***p<0.001.
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a cyclin A2-promoter luciferase reporter vector by cloning 
the 608 bp (-516 to +92) known to be essential for cyclin A2 
promoter activity (Fig. 3B) (12,13). The luciferase assay revealed 
a relatively 4-5-fold reduction in luciferase activity in the PAM- 
and ZOL-treated NHOKs (Fig. 3C), indicating that cyclin A2 
expression is indeed transcriptionally regulated by N-BPs.
N-BPs do not inhibit the expression of cyclin A2 in normal human 
oral fibroblasts (NHOFs). Our previous study demonstrated 
that N-BPs at the lower concentration had no notable effects on 
the proliferation of NHOFs (9). Thus, in this study, in order to 
examine whether cyclin A2 expression is altered by N-BPs in 
NHOFs, we treated the NHOFs with N-BPs and observed no 
changes in cyclin A2 expression at both the mRNA and protein 
level (Fig. 4A and B). Cyclin A2 promoter luciferase reporter 
assay revealed that there was also no change in luciferase activity 
in the NHOFs treated with the N-BPs (Fig. 4C), indicating that 
N-BPs at the concentrations which inhibited cyclin A2 in the 
NHOKs had no effects on cyclin A2 in the NHOFs.
Discussion
A significant body of evidence supports the notion that N-BPs 
cause epithelial toxicity. However, the underlying mechanisms 
are not yet fully understood. We previously demonstrated that 
bisphosphonates suppress proliferation without inducing the 
apoptosis of NHOKs (9). In this study, using microarray and 
IPA analyses, we found that N-BPs preferentially regulate genes 
associated with the cell cycle. Among the cell cycle-associated 
genes, the expression of cyclin A2 was specifically inhibited by 
the N-BPs in the NHOKs at the transcriptional level, and such 
an inhibition was not evident in the NHOFs, suggesting that the 
effects of BPs are cell type-specific. Furthermore, using oral 
epithelial tissue constructs, we demonstrated that BPs also cause 
the suppression of cyclin A2 in epithelial layers, indicating that 
epithelial toxicity by BPs is, at least in part, due to targeting 
cyclin A2 expression and suppressing cell proliferation.
N-BPs, derivatives of inorganic pyrophosphatase with 
a backbone of P-O-P, are stable and clinically applicable 
due to the replacement of oxygen molecule to the carbon 
molecule (P-C-P). This substitution enhances two independent, 
but synergistic biological properties of the bisphosphonates 
through the hydroxyl group (R1) and the nitrogen-containing 
group (R2) (14). The R1 group enhances the affinity to calcium-
enriched tissues, such as bone. On the other hand, the R2 group 
in BPs is the nitrogen-containing group, which is known to be 
responsible for an increase in biological potency by physically 
binding to and inhibiting the functions of farnesyl pyrophosphate 
synthase (FPPS) (15,16). FPPS is the key branch-point enzyme 
in the mevalonate pathway required for generating a metabolite, 
farnesyl pyrophosphate (FPP), for the synthesis of cholesterol and 
protein prenylation. Prenylation involves the transfer of farnesyl 
and/or geranylgeranyl lipid groups onto the C-terminus of small 
GTPase proteins at the post-translational level (17,18). As small 
GTPases, such as Ras, Rap1, Rab3A or RhoA are known to 
play pivotal roles in cellular functions, including proliferation, 
Figure 4. Bisphosphonates do not inhibit the expression of cyclin A2 in normal human oral fibroblasts (NHOFs). (A) NHOFs were treated with 10 µM 
pamidronate (PAM) for 4 days, and the expression of cyclin A2 was examined by RT-qPCR. (B) NHOFs were treated with 10 µM PAM for 4 days, or with 1 or 
2 µM zoledronate (ZOL) for 4 days. The expression of cyclin A2 was examined by western blot analysis. (C) Luciferase reporter assay was performed in NHOFs 
by transfecting this reporter vector in the presence of 2 µM ZOL.n.s., not significant.
Figure 3. Nitrogen-containing bisphosphonates (N-BPs) inhibit cyclin A2 expression at the transcriptional level. (A) Normal human oral keratinocytes (NHOKs) 
were treated with 10 µM pamidronate (PAM) for 2 or 4 days. NHOKs were also treated with 10 or 50 µM PAM for 4 days. Cyclin A2 expression was examined 
by RT-qPCR. (B) Cyclin A2 luciferase reporter vector was constructed by cloning the cyclin A2 promoter region (-516 to +92) into the pGL3-basic vector. 
(C) Luciferase reporter assay was conducted by transfecting this reporter vector into NHOKs without or with zoledronate (ZOL) or PAM.**p<0.01.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  40:  623-630,  2017 629
migration, morphology, polarity and secretion (19), BP-mediated 
changes in cellular functions may occur via the inhibition of the 
mevalonate pathway and protein prenylation.
A previous study found that the cyclin A2 gene was upregu-
lated by H-Ras and RhoA in their attempt to identify responsive 
genes by a group of different small GTPases (20). Of note, 
our recent study demonstrated that bisphosphonates inhibited 
cell cycle arrest at the S phase (9), suggesting that some small 
GTPases such as H-Ras or RhoA may be targeted by bisphos-
phonates to regulate transcriptional machineries to suppress 
expression of the downstream genes, such as cyclin A2.
The precise role of transcriptional regulation by bisphospho-
nates on cyclin A2 has yet to be determined. Although small 
GTPases are known to mainly regulate cytoskeletal structures and 
functions, studies showed modulation of transcriptional expres-
sion by these small GTPases. For instance, Rac and Cdc42 induce 
the transcriptional activity of c-Jun by activating c-Jun amino-
terminal kinawse (JNK), and Rho activates transcriptional activity 
of serum response factor (SRF) (21,22). RalA has also been shown 
to activate urokinase plasminogen activator receptor (uPAR) via 
c-Src and AP1 (23). Thus, it is likely that bisphosphonates inhibit 
cyclin A2 expression by disrupting prenylation and transcription-
activating functions of small GTPases.
It has been demonstrated that bisphosphonates have a poten-
tial role as putative cancer therapeutic agents. Bisphosphonate 
treatment induces the production of cytotoxic ATP analogs in 
tumor cells, leading to growth arrest (24). Bwisphosphonates also 
suppress angiogenesis via hypoxia-induction factor (HIF)-1α/
vascular endothelial growth factor (VEGF) signaling pathways 
in human breast cancer cells (25). Furthermore, bisphospho-
nates induce cell-cycle prolongation in murine lung cancer 
cells by alteration of cyclin and Ras expression (26). It has also 
been suggested that cyclin A2 may be the molecular target 
of the bisphosphonate-mediated suppression of cancer cells. 
Cyclin A2 is frequently found to be elevated in a variety of 
tumors (27). Ory et al showed that bisphosphonates inhibited 
the proliferation of osteosarcoma cells by inducing cell cycle 
arrest at the S and G2/M phase (28,29). In myeloma cells, 
bisphosphonates have also been shown to induce S phase cell 
cycle arrest by activating the MAPK pathway (11). The direct 
association between bisphosphonates and cyclin A2 warrants 
further investigation.
In conclusion, in this study, we demonstrate that cyclin A2, 
which regulates the cell cycle at the S phase by forming a 
cyclin A2-Cdk2 complex, is inhibited by both bisphosphonates, 
PAM and ZOL, at the transcriptional level. BPs targeting 
cyclin A2 expression may serve as the dominant mode of the cell 
cycle arrest and the inhibition of cell proliferation. Our 3-dimen-
sional (3D) oral mucosal tissue constructs also demonstrated 
that ZOL inhibited the expression of cyclin A2, suggesting that 
cyclin A2 may be involved in bisphosphonate-induced epithelial 
toxicity by causing structural and architectural damages. The 
modulation of cyclin A2 may hold therapeutic potential to 
ameliorate epithelial toxicity mediated by bisphosphonates.
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